3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
53
Neoplasm Metastasis
16
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
7
Brain Neoplasms
5
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Melanoma
3
Glioma
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Breast Diseases
3
Sarcoma, Ewing
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Glioblastoma
2
Advanced Cancer
2
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Rhabdomyosarcoma
1
Interventions
XENP 1595
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
glutathione pegylated liposomal doxorubicin
1
elacestrant
1
binimetinib
1
abemaciclib
1
Trastuzumab
1
Radiosurgery
1
RAD1901
1
PF-07284890
1
Midazolam
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Brain Diseases
×
abemaciclib
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled